9999999997-18-000639.txt : 20180201 9999999997-18-000639.hdr.sgml : 20180201 20180201155329 ACCESSION NUMBER: 9999999997-18-000639 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180201 DATE AS OF CHANGE: 20180201 ACTION DATE: 20180131 RECEIVED DATE: 20180201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HORIZON PHARMACEUTICAL LLC CENTRAL INDEX KEY: 0001070698 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860883978 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1933 Act SEC FILE NUMBER: 333-168966 FILM NUMBER: 18566822 BUSINESS ADDRESS: STREET 1: 7 HAMILTON LANDING STREET 2: SUITE 100 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-408-6200 MAIL ADDRESS: STREET 1: 7 HAMILTON LANDING STREET 2: SUITE 100 CITY: NOVATO STATE: CA ZIP: 94949 FORMER COMPANY: FORMER CONFORMED NAME: Raptor Pharmaceutical Corp DATE OF NAME CHANGE: 20090929 FORMER COMPANY: FORMER CONFORMED NAME: Raptor Pharmaceutical Corp. DATE OF NAME CHANGE: 20090929 FORMER COMPANY: FORMER CONFORMED NAME: TorreyPines Therapeutics, Inc. DATE OF NAME CHANGE: 20061003 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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